<DOC>
	<DOCNO>NCT00561574</DOCNO>
	<brief_summary>The current study 52-week safety study elderly outpatient chronic primary insomnia randomize treatment 1.5 mg 3.0 mg esmirtazapine ( Org 50081 , SCH 900265 , MK-8265 ) investigate safety tolerability long-term treatment esmirtazapine elderly patient .</brief_summary>
	<brief_title>A Long-Term Safety Study Org 50081 ( Esmirtazapine ) Elderly Outpatients With Chronic Primary Insomnia ( 176005/P05697/MK-8265-001 )</brief_title>
	<detailed_description>Insomnia common complaint disorder throughout world . About one third population industrial country report difficulty initiate maintain sleep , result non-refreshing non-restorative sleep . The majority insomniac suffer chronically complaint . The maleic acid salt Org 4420 , code name Org 50081 ( esmirtazapine ) , select development treatment insomnia . The first clinical trial esmirtazapine proof-of-concept trial four-way cross-over design . All 3 esmirtazapine dose group show statistically significant positive effect Total Sleep Time ( TST ) ( objective subjective ) Wake Time After Sleep Onset ( WASO ) , compare placebo . The current study 52-week safety study elderly outpatient chronic primary insomnia randomize treatment 1.5 mg 3.0 mg esmirtazapine investigate safety tolerability long-term treatment esmirtazapine elderly patient .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Disorders , Intrinsic</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>least 65 year age screening ; sign write informed consent scope nature investigation explain , screen evaluation ; able speak , read understand language investigator , study staff ( include raters ) inform consent form , possess ability respond question , follow instruction complete questionnaire ; demonstrate capability independently complete LogPad questionnaires week precede randomization ; normal bedtime within 21:00 01:00 hour range , variation 2 hour 5 night 7 ; document diagnosis chronic primary insomnia , define fulfillment Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIVTR ) criteria primary insomnia [ DSMIVTR 307.42 ] ) duration &gt; = 1 month ; fulfill follow criterion base medical sleep history . Each criteria present least 3 night per week least one month ; TST &lt; = 6.5 hour WASO &gt; = 60 minute Sleep Latency ( SL ) &gt; = 30 minute sleep disorder ( DSMIVTR ) e.g . rapid eye movement ( REM ) behavioral disorder , sleep related breathing disorder , periodic leg movement disorder , restless leg syndrome , narcolepsy , circadian sleep wake rhythm disorder , parasomnia ; significant medical DSMIVTR psychiatric illness cause sleep disturbance ; currently meet diagnostic criterion DSMIVTR depression ( Major Depressive Disorder [ MDD ] ) diagnose treat MDD within last 2 year ; sign dementia serious cognitive impairment , define score less 26 MiniMental State Examination ( MMSE ) ; history bipolar disorder , history suicide attempt family history suicide ; A family history suicide define history suicide first second degree family ( parent , sibling , grandparent , offspring ) , pattern complete suicide ( one ) third degree family ( aunt , uncle , niece , nephew ) ; night worker rotate shift worker ; travel , plan travel , three time zone trial , screen visit onwards ; significant , unstable medical illness e.g . acute chronic pain , hepatic , renal , metabolic cardiac disease ; clinically relevant electrocardiogram ( ECG ) abnormalities screen , judged investigator ; clinically relevant abnormal hematology biochemistry value screen , judged investigator ; DSMIVTR substance abuse DSMIVTR addiction within last year ; drink 2 alcoholic drink day . One drink approximately equal : 12 oz 360 mL beer ( regular light ) , 4 oz 120 mL red white wine , 2 oz 60 mL desert wine ( e.g . port , sherry ) , 12 oz 360 mL wine cooler ( regular light ) , 1 oz 30 mL spirit ( 80 100 proof , e.g . whiskey , vodka ) ; serious head injury stroke within past year , history ( nonfebrile ) seizure ; use psychotropic drug affect sleep within 2 week prior randomization ( fluoxetine : 5 week ) ; use concomitant medication affect sleep ( see Protocol Section 3.4 , Concomitant medication ) ; smoke &gt; 15 cigarette per day and/or abstain smoking night ; drink excessive amount caffeinated beverage ( 500 mg caffeine per day ) ; positive urine drug screen screening ; routinely sleep daytime ( nap ) 60 minute per day , 3 times/ week ; body mass index ( BMI ) &gt; = 36 ; know hypersensitivity mirtazapine excipients ; participate another clinical trial within last 30 day prior screen ; participate another clinical trial use esmirtazapine ( Org 50081 ) time .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>elderly</keyword>
	<keyword>randomize</keyword>
	<keyword>double blind</keyword>
</DOC>